Jianmin Dapeng

Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd. exclusively owns the complete intellectual property rights of in vitro cultured Calculus Bovis, a "National Class I New Traditional Chinese Medicine," and is a high-tech enterprise. It has repeatedly won honors such as the National High-tech Demonstration Base, Hubei Province "Specialized, Refined, Differentiated and Innovative" Little Giant Enterprise, and Hubei Province Innovative Pilot Enterprise. Since its establishment, the company has undertaken multiple national 863 programs and major provincial and municipal scientific and technological research projects. It possesses multiple patents and several national new drug varieties, and has successively won various honors including multiple national major technological inventions and key new products. Meanwhile, in vitro cultured Calculus Bovis was included in the 2005 edition of the Pharmacopoeia of the People's Republic of China. As a high-quality substitute for natural Calculus Bovis, it fundamentally solves the problem of scarce natural Calculus Bovis resources, is a hallmark of the modernization of traditional Chinese medicine, and currently supplies more than 3,000 hospitals and nearly 500 pharmaceutical factories, with broad market application prospects. Riding the fast track of policy dividends for traditional Chinese medicine development and responding to the national strategy of traditional Chinese medicine going global, the company is committed to building an upstream derivative platform for the core raw material industry of in vitro cultured Calculus Bovis, and is a "unicorn" hotly pursued by the capital market. To comprehensively advance an online-offline integrated high-tech health service model featuring Calculus Bovis as its specialty, the company is widely recruiting high-end business talent.